Treatment of lung cancer

Poster Discussion
Chairs: G. Hardavella (London, United Kingdom), D. Baldwin (Nottingham (Nottinghamshire), United Kingdom)

Efficacy and safety of anti-PD-L1 antibody in NSCLC patients who previously treated with anti PD-1 antibodies K. Fujita (Kyoto, Japan), N. Uchida (Kyoto, Japan), Y. Yamamoto (Kyoto, Japan), O. Kanai (Kyoto, Japan), M. Okamura (Kyoto, Japan), K. Nakatani (Kyoto, Japan), T. Mio (Kyoto, Japan)
Characteristics, incidence, risk factors, and practical management of pneumonitis associated with anti-PD-1 immunotherapy in patients with non-small cell lung cancer M. Moda (Kanagawa, Japan)
Positive PD-L1 expression is associated with unfavorable clinical outcome in EGFR-mutated lung adenocarcinomas treated with EGFR-TKIs J. Lee (Seoul, Republic of Korea), S. Lee (Seoul, Republic of Korea), B. Chang (Seoul, Republic of Korea), C. Choi (Seoul, Republic of Korea), Y. Kim (Seoul, Republic of Korea), H. Choi (Seoul, Republic of Korea), W. Kwak (Seoul, Republic of Korea), M. Park (Seoul, Republic of Korea), W. Jeon (Seoul, Republic of Korea)
Impact of nivolumab-induced fever on the treatment effect: a retrospective study O. Kanai (Kyoto, Japan), K. Fujita (Kyoto, Japan), M. Okamura (Kyoto, Japan), K. Horimoto (Kyoto, Japan), K. Takeda (Kyoto, Japan), M. Hashimoto (Kyoto, Japan), K. Nakatani (Kyoto, Japan), S. Sawai (Kyoto, Japan), T. Mio (Kyoto, Japan)
Immunological factors in NSCLC patients with possible predictive and prognostic value under PDL-1 treatment-a pilot study K. Domvri (Thessaloniki, Greece), N. Zogas (Thessaloniki, Greece), P. Zarogoulidis (Thessaloniki, Greece), K. Porpodis (Thessaloniki, Greece), E. Eleftheriadou (Thessaloniki, Greece), P. Chinelis (Thessaloniki, Greece), D. Bougiouklis (Thessaloniki, Greece), T. Tsiouda (Thessaloniki, Greece), T. Kontakiotis (Thessaloniki, Greece), K. Zarogoulidis (Thessaloniki, Greece)
Efficacy of osimertinib and histomolecular profile at progression in EGFR-mutated lung cancer C. Mehlman (Boulogne-Billancourt, France), J. Cadranel (Paris, France), R. Lacave (Paris, France), G. Rousseau-Bussac (Creteil, France), A. Pujals (Creteil, France), N. Girard (Paris, France), I. Bieche (Paris, France), V. Gounant (Paris, France), N. Théou-Anton (Paris, France), S. Friard (Suresnes, France), J. Trédaniel (Paris, France), H. Blons (Paris, France), C. Dujon (Versailles, France), B. Duchemann (Bobigny, France), P. Schischmanoff (Bobigny, France), T. Chinet (Boulogne-Billancourt, France), E. Giroux Leprieur (Boulogne-Billancourt, France)
Impact of antibiotics on immunotherapy response in lung cancer patients A. Alves (Vila Nova de Gaia , Portugal), I. Sucena (Vila Nova de Gaia , Portugal), M. Dias (Vila Nova de Gaia , Portugal), D. Coutinho (Vila Nova de Gaia , Portugal), T. Costa (Vila Nova de Gaia , Portugal), E. Silva (Vila Nova de Gaia , Portugal), S. Conde (Vila Nova de Gaia , Portugal), S. Campainha (Vila Nova de Gaia , Portugal), A. Barroso (Vila Nova de Gaia , Portugal)
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade in Lung Cancer – A restrospective study. C. Braço Forte (Setúbal, Portugal), T. Almodovar (Lisboa, Portugal), I. Duarte (Lisboa, Portugal), J. Duro Da Costa (Lisboa, Portugal)
Prognostic factors for stage IV NSCLC in older adults: A Surveillance, Epidemiology and End Results Database Analysis Y. Jian (Hangzhou, China)
Real-world treatment patterns and outcomes of patients with extensive disease small cell lung cancer (ED SCLC) C. Cramer - van der Welle (Utrecht, Netherlands), F. Schramel (Utrecht/Nieuwegein, Netherlands), A. Van Leeuwen (Utrecht, Netherlands), O. Klungel (Utrecht, Netherlands), H. Groen (Groningen, Netherlands), E. Van De Garde (Utrecht, Netherlands)
Systematic evaluation of the efficacy-effectiveness gap of systemic treatments in extensive disease small cell lung cancer (ED SCLC) C. Cramer - van der Welle (Utrecht, Netherlands), F. Schramel (Utrecht/Nieuwegein, Netherlands), B. Peters (Utrecht/Nieuwegein, Netherlands), O. Klungel (Utrecht, Netherlands), H. Groen (Groningen, Netherlands), E. Van De Garde (Utrecht, Netherlands)
Computed tomography-guided radiofrequency ablation and microwave ablation of non-small cell lung cancer metastases: Safety and efficacy in a real-world cohort K. Tavernaraki (Athens, Greece), I. Gkiozos (Athens, Greece), E. Kokkotou (Athens, Greece), D. Grapsa (Athens, Greece), I. Kotteas (Athens, Greece), L. Thanos (Athens, Greece), K. Syrigos (Athens, Greece), A. Charpidou (Athens, Greece)
Non-small Cell Lung Cancer as a chronic disease – a prospective study from the Czech TULUNG registry. M. Šatánková (Brno, Czech Republic), K. Brat (Brno, Czech Republic), J. Skrickova (Brno, Czech Republic), B. Karlinova (Brno, Czech Republic), M. Pesek (Pilsen, Czech Republic), V. Kolek (Olomouc, Czech Republic), L. Koubkova (Prague, Czech Republic), M. Hrnciarik (Hradec Kralove, Czech Republic), J. Krejci (Prague, Czech Republic), L. Havel (Prague, Czech Republic)
Clinical outcome of Pembrolizumab (PEMB) monotherapy in patients (pts) with advanced non-small cell lung cancer (NSCLC) – Reports from routine clinical care. Y. Kida (Kobe, Japan), A. Ikeda (Kobe, Japan), T. Ninomaru (Akashi, Japan), H. Ohnishi (Akashi, Japan), N. Katakami (Kobe, Japan)
SURGERY OF IA STAGE LUNG CARCINOMA. SUBLOBAR RESECTIONS. TO WHOM AND WHEN? A. Bazhenov (Ekaterinburg, Russian Federation), I. Motus (Ekaterinburg, Russian Federation), E. Altman (Nahariya, Israel), I. Medvinsky (Ekaterinburg, Russian Federation), M. Alexandrov (Ekaterinburg, Russian Federation)
Associations of gut microbiota and Chronic Obstructive Pulmonary Disease Assessment Test (CAT) score in chemotherapy treated lung cancer patients with COPD Z. Lohinai (Budapest, Hungary), Y. Heshiki (Jena, Germany), D. Loos (Jena, Germany), D. Nagy (Torokbalint, Hungary), E. Dulka (Torokbalint, Hungary), C. Kugler (Budapest, Hungary), J. Varga (Budapest, Hungary), M. Sommer (Lyngby, Denmark), G. Panagiotou (Jena, Germany), G. Weiss (Boston, United States of America)
Outcomes of pneumonectomy for N2 non small cell lung cancer S. Guinard (Strasbourg, France), A. Olland (Strasbourg, France), M. Puyraveau (Besançon, France), J. Seitlinger (Strasbourg, France), P. Falcoz (Strasbourg, France), G. Massard (Strasbourg, France)